Scotiabank Increases the Price Target for Vera Therapeutics by $10

Scotiabank analyst Greg Harrison maintained his Outperform rating on Vera Therapeutics, Inc. (NASDAQ:VERA) shares and raised his price objective from $55 to $65 for the company.

Scotiabank increases the price target for Vera Therapeutics by $10

A team of scientists in lab coats discussing research near a microscope and petri dishes.

The analyst informs investors that the business recently released positive topline data from the phase 3 ORIGIN study of atacicept, which showed that treatment with atacicept reduced proteinuria by 42% when compared to the placebo.

Despite the competitive environment, the company considers that it is in a good position to take a significant share of the expanding IgAN.

Vera Therapeutics, Inc. (NASDAQ:VERA) is a biotechnology startup in the clinical stage. Its main goal is to create and market revolutionary therapies for people suffering from severe immune disorders.

The company’s product candidate is atacicept, a fusion protein that is self-administered once a week via subcutaneous injection. It inhibits a proliferation-inducing ligand and a B lymphocyte stimulator, which cause B cells and plasma cells to produce autoantibodies that contribute to specific autoimmune diseases.

While we acknowledge the potential of VERA to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than VERA and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025.

Disclosure. None.